ABCG5 AND ABCG8: COMPOSITIONS AND METHODS OF USE
Patent Number:
Publication date: 2002-10-17
Inventor(s): BARNES ROBERT;; HOBBS HELEN H;; SHAN BEI;; TIAN HUI
Applicant(s): TULARIK INC (US); UNIV TEXAS (US)
Requested Patent: WO02081691
Application Number: WO2001US43823 20011120
Priority Number(s): US20000252235P 20001120; US20000253645P 20001128
(no link yet posted to application, no abstract)
J Lipid Res 2002 Nov;43(11):1864-74
Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte.
Repa JJ, Dietschy JM, Turley SD.
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390. Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390.
Intestinal cholesterol absorption is a major determinant of plasma low density lipoprotein-cholesterol (LDL-C) concentrations. Ezetimibe (SCH 58235) and its analogs SCH 48461 and SCH 58053 are novel potent inhibitors of cholesterol absorption whose mechanism of action is unknown. These studies investigated the effect of SCH 58053 on cholesterol metabolism in female 129/Sv mice. In mice fed a low cholesterol rodent diet containing SCH 58053, cholesterol absorption was reduced by 46% and fecal neutral sterol excretion was increased 67%, but biliary lipid composition and bile acid synthesis, pool size, and pool composition were unchanged. When the dietary cholesterol content was increased either 10- or 50-fold, those animals given SCH 58053 manifested lower hepatic and biliary cholesterol concentrations than did their untreated controls. Cholesterol feeding increased the relative mRNA level for adenosine triphosphate-binding cassette transporter A1 (ABCA1), ABC transporter G5 (ABCG5), and ABC transporter G8 (ABCG8) in the jejunum, and of ABCG5 and ABCG8 in the liver, but the magnitude of this increase was generally less if the mice were given SCH 58053. We conclude that the inhibition of cholesterol absorption effected by this new class of agents is not mediated via changes in either the size or composition of the intestinal bile acid pool, or the level of mRNA expression of proteins that facilitate cholesterol efflux from the enterocyte, but rather may involve disruption of the uptake of luminal sterol across the microvillus membrane. |
